The Zacks Analyst Blog Highlights:Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec
CHICAGO, March 6, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE:SNY-Free Report), Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Profit from Orphan Drugs: 3 Choices
Once given the moniker of orphans, drugs for rare diseases were originally considered to be an unviable proposition for pharma companies. This was because the number of patients for treatments was so small that their development and production were considered negligible. Today, they have emerged as major money earners for the pharma sector.
What Are Orphan Drugs?
Rare medical conditions were originally called "orphan diseases" simply because no one was providing treatments for them. The need for drugs targeted at rare conditions led to Congress creating the Orphan Drug Care Act of 1983. This offered companies a seven-year monopoly on medicines for rare diseases.
This offers the same protection to companies that a patent does, without having to clear the rigorous procedures a patent must go through. Again, orphan drug status can be given to drugs which are already being used in foreign markets, or in the U.S. itself for other diseases.
Money Makers
Such a development offered hope to patients with conditions as rare as hereditary angioedema. This condition affects only around six thousand people in the U.S. But these small numbers ultimately emerged as an advantage.
This is because pharma companies found they could make considerable profits from a small segment with relatively limited options. Treating patients with orphan drugs could cost anything between $200,000 to $600,000, leading to companies raking in billions.
Costs and Competition
The high cost of treatment may emerge as a roadblock in the long run. As attempts to reduce expenditures rise, pharma companies may find costs unsustainable. However, competition between drug makers is bringing down prices.
For example, Sanofi (NYSE:SNY-Free Report) produces Kynamro, used to treat a life-threatening inherited cholesterol disorder, which costs patients between $235,000 to $295,000 a year. In December 2013, Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR-Free Report) received approval for a cheaper alternative, Juxtapid. However, even this new medication will cost around $176,000 a year.
A Bright Future
Despite the obvious opportunities, not all aspiring orphan drug makers succeed because of the high costs and risks involved. However, the future looks bright according to a report released by research firm TechNavio. The orphan drugs sector is projected to grow globally at a CAGR of 5.67% from 2013 to 2018. This is primarily because of a reduction in the time required for drug development.
Below we present three stocks, each of which is involved with the orphan drugs sector and also have a good Zacks Rank. Incidentally, they also find mention in the TechNavio report.
Shire plc
Shire plc (Nasdaq:SHPG-Free Report) produces specialty biopharmaceutical treatments. It concentrates on medications for gastrointestinal conditions, attention deficit and hyperactivity disorder, regenerative medicine and human genetic therapies. It is currently developing a treatment for Sanfilippo syndrome, a rare metabolic condition.
Shire plc holds a Zacks Rank #1 (Strong Buy) and has expected earnings growth of 19.50%. The forward price-to-earnings ratio (P/E) for the current financial year (F1) is 17.41.
Amgen Inc.
Amgen Inc. (Nasdaq:AMGN-Free Report) is one of the world's largest biotechnology companies and much of its success is attributable to orphan drugs. It produces medications for kidney conditions, cancer, rheumatoid arthritis and bone diseases. It is a pioneer in the biotechnology arena and is involved in drug discovery, development and manufacturing.
Currently the company holds a Zacks Rank #2 (Buy) and has expected earnings growth of 7%. It has a P/E (F1) of 15.31.
Biogen Idec Inc.
Our third choice is Biogen Idec Inc. (Nasdaq:BIIB-Free Report). The company developed its drug Avonex when multiple sclerosis was still recognized as an orphan disease. It focuses on medication for autoimmune disorders, neurodegenerative diseases and hemophilia. Biogen is a Fortune 500 company with annual revenues of $5 billion.
Besides a Zacks Rank #1 (Strong Buy), Biogen Idec Inc. has expected earnings growth of 31.70%. It has a P/E (F1) of 28.96.
Drugs for rare conditions will continue to play a key role in the pharma sector in the future. Adding these excellent choices will go a long way in enhancing the value of your portfolio.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on SNY - FREE
Get the full Report on AEGR - FREE
Get the full Report on SHPG - FREE
Get the full Report on AMGN - FREE
Get the full Report on BIIB - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
Share this article